Navigation Links
Nektar Therapeutics' President and CEO, Howard W. Robin, to Present at the 30th Annual J.P. Morgan Healthcare Conference in San Francisco, CA
Date:1/4/2012

SAN FRANCISCO, Jan. 4, 2012 /PRNewswire/ -- Nektar Therapeutics' (Nasdaq: NKTR) President and Chief Executive Officer, Howard W. Robin, is scheduled to present at the upcoming 30th Annual J.P. Morgan Healthcare Conference in San Francisco at the Westin St. Francis Hotel on Wednesday, January 11, 2012 at 8:30 a.m. Pacific time.

The presentation will be accessible via a Webcast through a link posted on the Investor Relations, Events Calendar section of the Nektar website: http://www.nektar.com. This Webcast will be available for replay until February 12, 2012.

About Nektar

Nektar Therapeutics is a biopharmaceutical company developing novel therapeutics based on its PEGylation and advanced polymer conjugation technology platforms. Nektar's technology and drug development expertise have enabled seven approved products in the U.S. or Europe for leading biopharmaceutical company partners, including UCB's Cimzia(R) for Crohn's disease and rheumatoid arthritis, Roche's PEGASYS(R) for hepatitis C and Amgen's Neulasta(R) for neutropenia.

Nektar has created a robust pipeline of potentially high-value therapeutics to address unmet medical needs by leveraging and expanding its technology platforms to improve and enable molecules. In addition to the releasable polymer technology, Nektar is the first company to create a permanent small molecule-polymer conjugate with enhanced oral bioavailability and restricted entry into the CNS. Nektar is currently conducting clinical and preclinical programs in oncology, pain and other therapeutic areas. Nektar has an exclusive worldwide license agreement with AstraZeneca for its oral NKTR-118 program to treat opioid-induced constipation and its NKTR-119 program for the treatment of pain without constipation side effects. NKTR-181, a novel mu-opioid analgesic, has completed Phase 1 development and is being prepared for a Phase 2 study. NKTR-102 is being evaluated in a Phase 3 clinical study for the treatment of metastatic breast cancer and Phase 2 studies for the treatment of ovarian and colorectal cancers.

Nektar is headquartered in San Francisco, California, with additional R&D operations in Huntsville, Alabama and Hyderabad, India. Further information about the company and its drug development programs and capabilities may be found online at http://www.nektar.com.

CONTACT: Jennifer Ruddock, +1-415-482-5585


'/>"/>
SOURCE Nektar Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Nektar Therapeutics President and CEO, Howard W. Robin, to Present at UBS 2008 Global Life Sciences Conference in New York City
2. Nektar Therapeutics President and CEO Howard W. Robin to Present at Natixis Bleichroeder Second Annual Hidden Gems Conference in New York City
3. Nektar Sells Pulmonary Business to Novartis For $115 Million and Nektar Retains Key Pulmonary Programs Including Amikacin Inhale, Inhaled Vancomycin, and Ciprofloxacin Inhalation Powder
4. Nektar Therapeutics to Webcast R&D Day on November 12th
5. Nektar Announces Closing of Sale of Specific Pulmonary Delivery Assets to Novartis for $115 Million
6. Nektar Therapeutics President and CEO, Howard W. Robin, to Present at the 27th Annual J.P. Morgan Healthcare Conference in San Francisco
7. Nektar Announces Retirement of Irwin Lerner from Board of Directors
8. Nektar to Announce Year-End 2008 Financial Results on Wednesday, February 25, 2009 After Close of U.S.-Based Financial Markets
9. Nektar Therapeutics Reports Fourth Quarter and Year-End 2008 Financial Results
10. Nektar Therapeutics President and CEO, Howard W. Robin, to Present at the 29th Annual Cowen and Company Healthcare Conference in Boston
11. Nektar Therapeutics Reports First Quarter 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... ... January 18, 2017 , ... ... today announced that it has submitted a 510(k) to the FDA, requesting clearance ... MYOLYN’s patent-pending functional electrical stimulation (FES) technology. , The submission marks a ...
(Date:1/18/2017)... , ... January 18, 2017 , ... ... 24th, 2017, to sell research and genetic testing lab equipment from two different ... the Northwest and Northeast regions of the United States. This 1-day online auction ...
(Date:1/18/2017)... DIEGO , Jan. 18, 2017 Shareholder ... an investigation into whether the board members of CoLucid ... fiduciary duties in connection with the proposed sale of ... a biopharmaceutical company that develops small molecules for the ... 2017, CoLucid announced it had signed a definitive merger ...
(Date:1/18/2017)... TORONTO , Jan. 18, 2017 /PRNewswire/ - ... life sciences and diagnostics company that develops and ... diagnostics ("SQI" or the "Company"), today announced that ... Markets Inc. ("Kingsdale"), has resigned from its Board ... recent changes to securities regulations that have limited ...
Breaking Biology Technology:
(Date:12/15/2016)... 15, 2016  There is much more to innovative ... the engine. Continental will demonstrate the intelligence of today,s ... . Through the combination of the keyless entry ... biometric elements, the international technology company is opening up ... authentication. "The integration of biometric elements brings ...
(Date:12/12/2016)... Dec. 12, 2016  Researchers at Trinity College, ... graphene by combining the material with Silly Putty. The ... pressure detector able to sense pulse, blood pressure, ... spider.  The research team,s findings ... read here:  http://science.sciencemag.org/content/354/6317/1257 ...
(Date:12/8/2016)... 8, 2016  Singulex, Inc., the leader in Next ... into a license and supply agreement with Thermo Fisher ... provides Singulex access to Thermo Scientific BRAHMS PCT (Procalcitonin), ... is used to diagnose systemic bacterial infection and sepsis ... to aid in assessing the risk of critically ill ...
Breaking Biology News(10 mins):